SOAM
RARE icon

SBI Okasan Asset Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

SBI Okasan Asset Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$442K Hold
14,400
– – 0.01% 222
2026
Q1 		$278K Hold
14,400
– – 0.01% 228
2025
Q4 		$284K Buy
+14,400
New +$474K 0.02% 220

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

SBI Okasan Asset Management's RARE Position: Q2 2026 in Review

SBI Okasan Asset Management held its Ultragenyx Pharmaceutical (RARE) position steady in Q2 2026 at 14,400 shares worth $442K. The position accounts for 0.01% of the portfolio, ranked #222.

SBI Okasan Asset Management first reported a position in RARE in Q4 2025 and has held it in 3 quarters since. 310 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • SBI Okasan Asset Management held 14,400 shares of Ultragenyx Pharmaceutical worth $442K as of Q2 2026.
  • SBI Okasan Asset Management left its Ultragenyx Pharmaceutical share count unchanged in Q2 2026.
  • Ultragenyx Pharmaceutical made up 0.01% of SBI Okasan Asset Management's portfolio in Q2 2026, its #222 holding.
  • SBI Okasan Asset Management first reported a position in Ultragenyx Pharmaceutical in Q4 2025 and has held it in 3 quarters since.
  • 310 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on SBI Okasan Asset Management's 13F filing for Q2 2026, filed 22 Jul 2026.